TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15813475

Group type: EXPERIMENTAL
Intervention: Estrogen and progesterone
Number of subjects: 52

Group type: COMPARATOR
Intervention: Progesterone alone
Number of subjects: 52
Study: 11182260

Group type: EXPERIMENTAL
Intervention: PharmChek sweat patch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal hygiene and cleaning procedures
Number of subjects: 0
Study: 9480227

Group type: EXPERIMENTAL
Intervention: Placentas from Płock's area
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group (Placentas from Kutno)
Number of subjects: 226
Study: 7942084

Group type: EXPERIMENTAL
Intervention: Gonadotropins only (group A)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Gonadotropin releasing hormone analog plus gonadotropins (group B)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Gonadotropins only (group A) with low progesterone levels (< or = 1 ng/ml)
Number of subjects: 160
Study: 3061183

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.i.d. over 4-8 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 31395858

Group type: EXPERIMENTAL
Intervention: High energy turnover (ET) during caloric restriction (CR)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High energy turnover (ET) during overfeeding (OF)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low energy turnover (ET) during caloric restriction (CR)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Medium energy turnover (ET) during caloric restriction (CR)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low energy turnover (ET) during overfeeding (OF)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Medium energy turnover (ET) during overfeeding (OF)
Number of subjects: 16
Study: 27496336

Group type: EXPERIMENTAL
Intervention: PA21 (sucroferric oxyhydroxide)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Sevelamer hydrochloride
Number of subjects: 213

Group type: COMPARATOR
Intervention: Both PA21 and Sevelamer
Number of subjects: 213
Study: 25488826

Group type: EXPERIMENTAL
Intervention: Vitamin D‐binding protein SNPs (rs4588‐A)
Number of subjects: 3275

Group type: EXPERIMENTAL
Intervention: Vitamin D‐binding protein SNPs (rs7041‐T)
Number of subjects: 3275

Group type: EXPERIMENTAL
Intervention: Low 25(OH)D metabolism score
Number of subjects: 3275

Group type: EXPERIMENTAL
Intervention: CYP24A1 SNP (rs6013897‐A)
Number of subjects: 3275

Group type: EXPERIMENTAL
Intervention: CYP27B1 SNP (rs10877012‐T)
Number of subjects: 3275
Study: 23395396

Group type: EXPERIMENTAL
Intervention: Comfilcon A
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Etafilcon A
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Senofilcon A, Lotrafilcon B, Balafilcon A
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Lens wear
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Lens modulus and edge shapes (knife and chisel)
Number of subjects: 36
Study: 21575826

Group type: EXPERIMENTAL
Intervention: FACE Advance Care Planning intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Healthy Living Control group
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Surrogates
Number of subjects: 80
Study: 19928724

Group type: EXPERIMENTAL
Intervention: Preoperative Nd:YAG laser anterior capsulotomy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Two-stage continuous curvilinear capsulorhexis (CCC)
Number of subjects: 23
Study: 17021422

Group type: EXPERIMENTAL
Intervention: Milk (300 ml)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Water (300 ml)
Number of subjects: 198
Study: 14738654

Group type: EXPERIMENTAL
Intervention: Midwives
Number of subjects: 19

Group type: COMPARATOR
Intervention: Senior House Officers (SHOs)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 19
Study: 11380417

Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cells
Number of subjects: 67

Group type: COMPARATOR
Intervention: Marrow
Number of subjects: 67
Study: 9160360

Group type: EXPERIMENTAL
Intervention: Protamine infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: CABG group
Number of subjects: 0
Study: 8106650

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg once daily for 6 weeks)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Fluoxetine (20 mg once daily for 6 weeks)
Number of subjects: 178
Study: 3492156

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of propofol at 54 micrograms X kg‐1 X min‐1 (group 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of propofol at 108 micrograms X kg‐1 X min‐1 (group 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlled ventilation to decrease arterial PCO2 to awake value
Number of subjects: 0
Study: 30155865

Group type: EXPERIMENTAL
Intervention: TrueCPR device
Number of subjects: 65

Group type: COMPARATOR
Intervention: Manual chest compressions
Number of subjects: 65
Study: 28693976

Group type: EXPERIMENTAL
Intervention: Spirometry 360 distance learning quality improvement program
Number of subjects: 626

Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 626
Study: 25873529

Group type: EXPERIMENTAL
Intervention: Flexible self-adherent absorbent dressing coated with a soft silicone layer
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard wound dressing
Number of subjects: 100
Study: 23524149

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion at a rate of 0.4 μg kg(‐1) h(‐1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline infusion (placebo)
Number of subjects: 100
Study: 21406694

Group type: EXPERIMENTAL
Intervention: Silicone gel sheeting
Number of subjects: 30

Group type: COMPARATOR
Intervention: Emollient cream
Number of subjects: 30
Study: 19134170

Group type: EXPERIMENTAL
Intervention: Acupuncture in addition to usual GP care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-directive counselling in addition to usual GP care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acupuncture and counselling arms split into two groups to explore different treatment regimens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 17264030

Group type: EXPERIMENTAL
Intervention: Radial-cephalic arteriovenous fistula
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Primary radial-cephalic arteriovenous fistula
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Elbow brachiocephalic fistulas
Number of subjects: 13
Study: 15313358

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 5103

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 5103

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 5103

Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (BMS)
Number of subjects: 5103

Group type: EXPERIMENTAL
Intervention: Polymer-based paclitaxel-eluting stents
Number of subjects: 5103

Group type: COMPARATOR
Intervention: Polymer-based paclitaxel-eluting stents (BMS)
Number of subjects: 5103

Group type: EXPERIMENTAL
Intervention: Non-polymer-based paclitaxel-eluting stents
Number of subjects: 5103

Group type: COMPARATOR
Intervention: Non-polymer-based paclitaxel-eluting stents (BMS)
Number of subjects: 5103
Study: 11369685

Group type: EXPERIMENTAL
Intervention: Short oral anticoagulant course (3 months for P-DVT/PE; 6 weeks for C-DVT)
Number of subjects: 736

Group type: COMPARATOR
Intervention: Long oral anticoagulant course (6 months for P-DVT/PE; 12 weeks for C-DVT)
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Short oral anticoagulant course
Number of subjects: 736

Group type: COMPARATOR
Intervention: Long oral anticoagulant course
Number of subjects: 736
Study: 9272331

Group type: EXPERIMENTAL
Intervention: Whole-cell pertussis vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccines
Number of subjects: 0
Study: 8490744

Group type: EXPERIMENTAL
Intervention: Propofol alone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Midazolam alone
Number of subjects: 60
Study: 2890669

Group type: EXPERIMENTAL
Intervention: Bucindolol 100 mg/d
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Bucindolol 200 mg/d
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Bucindolol 300 mg/d
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg/d
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Propranolol 320 mg/d
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Bucindolol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 6
Study: 30103679

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (1 mcg/Kg bolus followed by 1 mcg/Kg/hour for 90 min)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Normal saline infusion (Control group)
Number of subjects: 42
Study: 26718688

Group type: EXPERIMENTAL
Intervention: RVF MP‐12, administered subcutaneously (SQ) at a concentration of 10(4.7) plaque‐forming units (pfu)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: RVF MP‐12, administered intramuscularly (IM) at 10(3.4) pfu (IM Group 1)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: RVF MP‐12, administered IM at 10(4.4) pfu (IM Group 2)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Saline (Placebo Group)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: RVF MP‐12 (all groups)
Number of subjects: 56
Study: 24581321

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural rehabilitation intervention (patient education focusing on pain behaviour and pain coping)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural rehabilitation intervention
Number of subjects: 96
Study: 22965404

Group type: EXPERIMENTAL
Intervention: Colonic irrigation and oral antibiotics (1 L of tap water daily and a 1-week course of ciprofloxacin and metronidazole)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 4% formalin application (for 3 minutes)
Number of subjects: 50
Study: 20944503

Group type: EXPERIMENTAL
Intervention: d-amphetamine (8, 16, and 24 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: d-amphetamine (0, 8, 16, and 24 mg)
Number of subjects: 8
Study: 18977988

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Prophylaxis (co-trimoxazole 15 mg/kg per day or co-amoxiclav 15 mg/kg per day for 12 months)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Prophylaxis (co-trimoxazole or co-amoxiclav)
Number of subjects: 338
Study: 16209161

Group type: EXPERIMENTAL
Intervention: Adapalene gel 0.3%
Number of subjects: 214

Group type: COMPARATOR
Intervention: Adapalene gel 0.1%
Number of subjects: 214

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 214
Study: 11834535

Group type: EXPERIMENTAL
Intervention: HypoALP
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: HyperALP
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Hyperlipidemic subjects (n=559)
Number of subjects: 110
Study: 10518234

Group type: EXPERIMENTAL
Intervention: 50 mg/m2 intramuscular methotrexate on day 1
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 800 micrograms vaginal misoprostol on day 1
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 50 mg/m2 intramuscular methotrexate followed by 800 micrograms vaginal misoprostol 3 days later
Number of subjects: 108
Study: 7898846

Group type: EXPERIMENTAL
Intervention: Low-dose monophasic oral contraceptives (OCs)
Number of subjects: 87

Group type: COMPARATOR
Intervention: No OCs or other hormonally active medications
Number of subjects: 87
Study: 1456487

Group type: EXPERIMENTAL
Intervention: Immunotherapy with wheat flour
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 26
Study: 6697889

Group type: EXPERIMENTAL
Intervention: Timed-release tablet containing carbinoxamine maleate 8 mg and pseudoephedrine hydrochloride 120 mg
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Timed-release tablet
Number of subjects: 94
Study: 31230110

Group type: EXPERIMENTAL
Intervention: Full squat training (FST)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Half squat training (HST)
Number of subjects: 17
Study: 29764341

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (CBGT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Group psychotherapy (GPT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (non-specific factors in GPT)
Number of subjects: 45
Study: 24898552

Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 106

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 106
Study: 22596242

Group type: EXPERIMENTAL
Intervention: Cancer Registration (CR)
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Self-reporting
Number of subjects: 1065

Group type: COMPARATOR
Intervention: BCQ (gold standard)
Number of subjects: 1065
Study: 19170164

Group type: EXPERIMENTAL
Intervention: Large-volume-apheresis (LVA)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control (group-A and group-B)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control (group-B)
Number of subjects: 226
Study: 17250613

Group type: EXPERIMENTAL
Intervention: Gabapentin (up to 1,200 mg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 35
Study: 15748221

Group type: EXPERIMENTAL
Intervention: Screening for elevated levels of homocysteine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment of hyperhomocysteinemia
Number of subjects: 0
Study: 12634571

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (40,000 units injected subcutaneously)
Number of subjects: 48
Study: 9682390

Group type: EXPERIMENTAL
Intervention: SB DTaP vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CB DTaP vaccine
Number of subjects: 0
Study: 7800902

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg p.o. plus metoclopramide 10 mg p.o. (metoclopramide group, n = 322)
Number of subjects: 637

Group type: COMPARATOR
Intervention: Diazepam 10 mg p.o. (control group, n = 315)
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Both groups (metoclopramide and control)
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Comparison of patients with and without nausea
Number of subjects: 637
Study: 3153710

Group type: EXPERIMENTAL
Intervention: Yohimbine (YOH) 0.8 mg/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 10 mg/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Diazepam (DZ) 0.3 mg/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Clonidine (CLO) 100 micrograms
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Clonidine (CLO) 200 micrograms
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Diazepam (DZ)
Number of subjects: 16
Study: 31822251

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase (doses not specified)
Number of subjects: 4016

Group type: EXPERIMENTAL
Intervention: Utility-weighted mRS scores derived from the study
Number of subjects: 4016

Group type: EXPERIMENTAL
Intervention: Thrombolysis treatment
Number of subjects: 4016
Study: 29182412

Group type: EXPERIMENTAL
Intervention: Water loading (100 ml/kg for Days 1-3, 15 ml/kg on Day 4)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Water loading
Number of subjects: 21

Group type: COMPARATOR
Intervention: Water loading and control
Number of subjects: 21
Study: 28068834

Group type: EXPERIMENTAL
Intervention: Light sedation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heavy sedation
Number of subjects: 0
Study: 26248357

Group type: EXPERIMENTAL
Intervention: 250 mg cadazolid BID
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 500 mg cadazolid BID
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 1,000 mg cadazolid BID
Number of subjects: 84

Group type: COMPARATOR
Intervention: 125 mg vancomycin QID
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Cadazolid (all dosages)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Cadazolid and vancomycin
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Cadazolid
Number of subjects: 84
Study: 23347400

Group type: EXPERIMENTAL
Intervention: Ultra-low-dose vaginal estriol 0.03 mg in combination with Lactobacillus acidophilus KS400 (Gynoflor(®) vaginal tablets)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Ultra-low-dose vaginal estriol 0.03 mg in combination with Lactobacillus acidophilus KS400 (Gynoflor(®) vaginal tablets) during maintenance therapy
Number of subjects: 87
Study: 21937987

Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ritonavir
Number of subjects: 16
Study: 18226399

Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine (NAC) during hemodialysis
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hemodialysis alone (Control)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison of NAC vs. Hemodialysis alone
Number of subjects: 40
Study: 16606393

Group type: EXPERIMENTAL
Intervention: Low dose fluoroscopy regime
Number of subjects: 235
Study: 14720434

Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 884

Group type: COMPARATOR
Intervention: Anticoagulation
Number of subjects: 884
Study: 10952951

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/d)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 8772759

Group type: EXPERIMENTAL
Intervention: Propafenone 750 mg/day for 48 hours before cardioversion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 1408320

Group type: EXPERIMENTAL
Intervention: Acetaminophen (1000 mg, orally)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Antipyrine (1000 mg, orally)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 3892996

Group type: EXPERIMENTAL
Intervention: Intravenous indomethacin 100 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 20
Study: 31533906

Group type: EXPERIMENTAL
Intervention: Patiromer (8·4 g once daily)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study: 29192000

Group type: EXPERIMENTAL
Intervention: Hyoscine patch
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Glycopyrronium liquid
Number of subjects: 90
Study: 27385502

Group type: EXPERIMENTAL
Intervention: Topical high-dose combination of clonidine (0.1%) + pentoxifylline (5%)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Topical low-dose combination of clonidine (0.04%) + pentoxifylline (2%)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Clonidine (0.1%) alone
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (5%) alone
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo treatments for both low-dose and high-dose combinations
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: High-dose combination of clonidine + pentoxifylline
Number of subjects: 69
Study: 25042266

Group type: EXPERIMENTAL
Intervention: Transradial (TR) approach
Number of subjects: 260

Group type: COMPARATOR
Intervention: Transfemoral (TF) approach
Number of subjects: 260
Study: 22435321

Group type: EXPERIMENTAL
Intervention: Waterpik Water Flosser (WF) plus manual tooth brushing
Number of subjects: 82

Group type: COMPARATOR
Intervention: Sonicare Air Floss (AF) plus manual tooth brushing
Number of subjects: 82
Study: 20482830

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Change in executive functions and falls-related self-efficacy
Number of subjects: 135
Study: 18628468

Group type: EXPERIMENTAL
Intervention: PF‐3512676
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 24
Study: 15892287

Group type: EXPERIMENTAL
Intervention: Qingyuan decoction combined with antibiotics
Number of subjects: 96

Group type: COMPARATOR
Intervention: Antibiotics alone
Number of subjects: 96
Study: 12131831

Group type: EXPERIMENTAL
Intervention: Snoezelen sensory environment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional relaxation
Number of subjects: 0
Study: 10428519

Group type: EXPERIMENTAL
Intervention: 100 mg aspirin daily for > or = 14 days
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo for > or = 14 days
Number of subjects: 99
Study: 7752866

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (Se), N = 12, during a 10-week endurance training program.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (Pla), N = 12, during a 10-week endurance training program.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Endurance training (both groups), N = 24.
Number of subjects: 24
Study: 2298828

Group type: EXPERIMENTAL
Intervention: Nimodipine (2 mg/h constant i.v. infusion for 5 days, 120 mg/day orally for another 16 days)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 12085574

Group type: EXPERIMENTAL
Intervention: Reuse of plastic disposable needle-syringe units
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glass syringes with daily new needles
Number of subjects: 0
Study: 31683132

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR) and music therapy
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (CG) - took the exam as usual
Number of subjects: 112
Study: 31855202

Group type: EXPERIMENTAL
Intervention: Acculink stents
Number of subjects: 50

Group type: COMPARATOR
Intervention: CGuard stents
Number of subjects: 50
Study: 27669524

Group type: EXPERIMENTAL
Intervention: Screening colonoscopy
Number of subjects: 1355692

Group type: COMPARATOR
Intervention: No screening
Number of subjects: 1355692
Study: 26467764

Group type: EXPERIMENTAL
Intervention: 12 sessions of aerobic exercise at preferred intensity alongside treatment as usual
Number of subjects: 87

Group type: COMPARATOR
Intervention: treatment as usual only
Number of subjects: 87
Study: 23300303

Group type: EXPERIMENTAL
Intervention: Bacillus subtilis PB6 at 500 g/t of feed, containing 5 × 10(11) cfu/kg
Number of subjects: 216

Group type: COMPARATOR
Intervention: Infected control group (no supplementation)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Uninfected control group (no infection or supplementation)
Number of subjects: 216